Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.43 |
| ▸ | SCD | O00767 | 1/20 | 0.39 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | VNN1 | O95497 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29927414 | 1.00 | RIPK1 (0.43) | RIPK1SCDCTDSP1ROCK2JAK2 | |
| SCHEMBL23075410 | 0.84 | RIPK1 (0.42) | RIPK1SCDROCK2MGLLGRM5 | |
| SCHEMBL29842483 | 0.84 | RIPK1 (0.42) | RIPK1SCDROCK2MGLLGRM5 | |
| SCHEMBL23067722 | 0.82 | RIPK1 (0.45) | RIPK1CTDSP1CYP1A2VNN1NAMPT | |
| SCHEMBL29842646 | 0.81 | RIPK1 (0.43) | RIPK1SCDROCK2JAK2JAK1 | |
| SCHEMBL23075373 | 0.81 | RIPK1 (0.43) | RIPK1SCDROCK2JAK2JAK1 | |
| SCHEMBL29926795 | 0.80 | TBXAS1 (0.43) | RIPK1SCDGRM5GRM1GPR119 | |
| SCHEMBL23075395 | 0.80 | TBXAS1 (0.43) | RIPK1SCDGRM5GRM1GPR119 | |
| SCHEMBL23075419 | 0.80 | RIPK1 (0.45) | RIPK1SCDROCK2MGLL | |
| SCHEMBL29842599 | 0.80 | RIPK1 (0.45) | RIPK1SCDROCK2MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331036-B2 | Heterocyclic RIP1 kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| EP-4025572-B1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2025-05-07 | — | — | EP | disclosed |
| US-12156880-B2 | Heterocyclic RIP1 kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2024-12-03 | — | — | US | disclosed |
| EP-4304713-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| CN-117083270-A | Heterocyclic RIP1 kinase inhibitors | 里格尔药品股份有限公司 | 2023-11-17 | — | — | CN | disclosed |
| US-20230057341-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2023-02-23 | — | — | US | disclosed |
| US-20230057341-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2023-02-23 | — | — | US | disclosed |
| US-11479543-B2 | Heterocyclic RIP1 kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2022-10-25 | — | — | US | disclosed |
| US-20220296608-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | MIDCAP FINANCIAL TRUST | 2022-09-22 | — | — | US | disclosed |
| WO-2022192533-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| CN-114761398-A | Heterocyclic RIP1 kinase inhibitors | 里格尔药品股份有限公司 | 2022-07-15 | — | — | CN | disclosed |
| US-20210070744-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-11 | — | — | US | disclosed |
| WO-2021046447-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11479543-B2 | Heterocyclic RIP1 kinase inhibitors | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885SCD 1636/4885CTDSP1 1240/4885 |
| US-20210070744-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885SCD 1636/4885CTDSP1 1240/4885 |
| US-20220296608-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885SCD 1636/4885CTDSP1 1240/4885 |
| US-12156880-B2 | Heterocyclic RIP1 kinase inhibitors | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885SCD 1636/4885CTDSP1 1240/4885 |
| US-20230057341-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885SCD 1636/4885CTDSP1 1240/4885 |
| US-12331036-B2 | Heterocyclic RIP1 kinase inhibitors | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885SCD 1636/4885CTDSP1 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.